Advertisement

HBV/HCV Co-infection and Mixed Cryoglobulinemia

  • Massimo Galli
  • Salvatore Sollima
Chapter

Abstract

It is estimated that 35–50 million people are chronically co-infected with HBV and HCV worldwide. In mono-infected patients, both viruses have been associated with numerous extrahepatic manifestations. Among these, polyarteritis nodosa and glomerulonephritis are most frequently documented in HBV and mixed cryoglobulinemia (MC) in HCV cases. With the exception of anecdotal observations, there are no data regarding MC in individuals with dual chronic infection by HCV and overt or occult HBV. Based on the interplay between the two viruses in infected patients, extrahepatic manifestations can be attributed to one or the other virus, in either a dominant or co-dominant role; however, this relationship may change over time, either spontaneously or as a consequence of therapy. Furthermore, equal or at least synergistic roles of HBV and HCV in triggering the production of cryoglobulins in some patients with overt or occult co-infection cannot be excluded. An attempt at viral eradication or sustained suppression of viral replication is indicated in all patients with cryoglobulinemic syndrome and HBV/HCV co-infection, after an accurate assessment of the activity/severity of the vasculitis and the underlying liver disease. Furthermore, due to the variable virological patterns, a careful longitudinal evaluation of the viremia levels of both HBV and HCV is mandatory prior to the initiation of antiviral therapy, in order to assess the patient’s current virological status and thereby determine the most appropriate therapeutic regimen.

Keywords

Mixed Cryoglobulinemia Extrahepatic Manifestation Essential Cryoglobulinemia Mixed Cryoglobulinemia Syndrome Oral Nucleos 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Chu CJ, Lee SD (2008) Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 23:512–520PubMedCrossRefGoogle Scholar
  2. 2.
    Pontisso P, Ruvoletto MG, Fattovich G et al (1993) Clinical and virological profiles in patients with multiple hepatitis infections. Gastroenterology 105:1529–1533PubMedCrossRefGoogle Scholar
  3. 3.
    Sato S, Fujiyama S, Tanaka M et al (1994) Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 21:159–166PubMedCrossRefGoogle Scholar
  4. 4.
    Crespo J, Lozano JL, de la Cruz F et al (1994) Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 89:1147–1151PubMedGoogle Scholar
  5. 5.
    Alberti A, Pontisso P, Chemello L et al (1995) The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 22(Suppl 1):S38–S41Google Scholar
  6. 6.
    Zarski JP, Bohn B, Bastie A et al (1998) Characteristic of patients with dual infection by hepatitis B and C viruses. J Hepatol 28:27–33PubMedCrossRefGoogle Scholar
  7. 7.
    Raimondo G, Brunetto MR, Pontisso P et al (2006) Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43:100–107PubMedCrossRefGoogle Scholar
  8. 8.
    Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97–107PubMedCrossRefGoogle Scholar
  9. 9.
    Gaeta GB, Stornaiuolo G, Precone DF et al (2003) Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 39:1036–1041PubMedCrossRefGoogle Scholar
  10. 10.
    Sagnelli E, Pasquale G, Coppola N et al (2004) Influence of chronic co-infection with hepatitis B and C virus on liver histology. Infection 32:144–148PubMedCrossRefGoogle Scholar
  11. 11.
    Lee LP, Dai CY, Chuang WL et al (2007) Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 22:515–517PubMedCrossRefGoogle Scholar
  12. 12.
    Fattovich G, Tagger A, Brollo L et al (1991) Hepatitis virus infection in chronic hepatitis B virus carriers. J Infect Dis 163:400–402PubMedCrossRefGoogle Scholar
  13. 13.
    Simonetti RG, Cammà C, Fiorello F et al (1992) Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 116:97–102PubMedCrossRefGoogle Scholar
  14. 14.
    Benvegnù L, Fattovich G, Noventa F et al (1994) Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 74:2442–2448PubMedCrossRefGoogle Scholar
  15. 15.
    Liaw YF (1995) Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 22:1101–1108PubMedGoogle Scholar
  16. 16.
    Shih CM, Lo SJ, Miyamura T et al (1993) Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Hu-H7 cells. J Virol 67:5823–5832PubMedGoogle Scholar
  17. 17.
    Shih CM, Chen CM, Chen SY, Lee YH (1995) Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 69:1160–1171PubMedGoogle Scholar
  18. 18.
    Schuttler CG, Fiedler N, Schmidt K et al (2002) Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 37:855–862PubMedCrossRefGoogle Scholar
  19. 19.
    Chen SY, Kao CF, Chen CM et al (2003) Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 278:591–607PubMedCrossRefGoogle Scholar
  20. 20.
    Sheen IS, Liaw YF, Chu CM, Pao CC (1992) Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 165:831–834PubMedCrossRefGoogle Scholar
  21. 21.
    Chu CM, Yeh CT, Liaw YF (1998) Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 36:2084–2086PubMedGoogle Scholar
  22. 22.
    Jardi R, Rodriguez F, Buti M et al (2001) Role of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 34:404–410PubMedCrossRefGoogle Scholar
  23. 23.
    Squadrito G, Orlando ME, Pollicino T et al (2002) Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 97:1518–1523PubMedCrossRefGoogle Scholar
  24. 24.
    Sagnelli E, Coppola N, Scolastico C et al (2000) Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 32:1106–1110PubMedCrossRefGoogle Scholar
  25. 25.
    Ohkawa K, Hayashi N, Yuki N et al (1994) Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol 21:509–514PubMedCrossRefGoogle Scholar
  26. 26.
    Ohkawa K, Hayashi N, Yuki N et al (1995) Long-term follow up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 46:258–264PubMedCrossRefGoogle Scholar
  27. 27.
    Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170PubMedCrossRefGoogle Scholar
  28. 28.
    Ganem D, Prince AM (2004) Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 350:1118–1129PubMedCrossRefGoogle Scholar
  29. 29.
    Zoulim F (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 42:302–308PubMedCrossRefGoogle Scholar
  30. 30.
    Yamamoto K, Horikita M, Tsuda F et al (1994) Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68:2671–2676PubMedGoogle Scholar
  31. 31.
    Kreutz C (2002) Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 6:113–143PubMedCrossRefGoogle Scholar
  32. 32.
    Jeantet D, Chemin I, Mandrand B et al (2004) Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 73:508–515PubMedCrossRefGoogle Scholar
  33. 33.
    Chaudhuri V, Tayal R, Nayak B et al (2004) Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 127:1356–1371PubMedCrossRefGoogle Scholar
  34. 34.
    Pollicino T, Raffa G, Costantino L et al (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277–285PubMedCrossRefGoogle Scholar
  35. 35.
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 10:1104–1108CrossRefGoogle Scholar
  36. 36.
    Guidotti LG, Rochford R, Chung J et al (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825–829PubMedCrossRefGoogle Scholar
  37. 37.
    Cacciola I, Pollicino T, Squadrito G et al (1999) Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22–26PubMedCrossRefGoogle Scholar
  38. 38.
    Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2:479–486PubMedCrossRefGoogle Scholar
  39. 39.
    Liu CJ, Lo SC, Kao JH et al (2006) Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 44:39–46PubMedCrossRefGoogle Scholar
  40. 40.
    Chazouilleres O, Mamish D, Kim M et al (1994) Occult hepatitis B virus as source of infection in liver transplant recipients. Lancet 343:142–146PubMedCrossRefGoogle Scholar
  41. 41.
    Wachs ME, Amend WJ, Ascher NL et al (1995) The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 59:230–234PubMedGoogle Scholar
  42. 42.
    Lok ASF, Liang RHS, Chiu EKW et al (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 100:182–188PubMedGoogle Scholar
  43. 43.
    Dhedin N, Douvin C, Kuentz M et al (1998) Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66:616–619PubMedCrossRefGoogle Scholar
  44. 44.
    Abdelmalek MF, Pasha TM, Zein NN et al (2003) Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 9:1253–1257PubMedGoogle Scholar
  45. 45.
    Onozawa M, Hashino S, Izumiyama K et al (2005) Pro­gressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hemato­poietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79:616–619PubMedCrossRefGoogle Scholar
  46. 46.
    Zhang YY, Hansson BG, Kuo LS et al (1993) Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 17:538–544PubMedCrossRefGoogle Scholar
  47. 47.
    Sagnelli E, Coppola N, Scolastico C et al (2001) HCV genotype and “silent” HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 64:350–355PubMedCrossRefGoogle Scholar
  48. 48.
    Chemin I, Trepo C (2005) Clinical impact of occult HBV infections. J Clin Virol 34(Suppl 1):S15–S21PubMedCrossRefGoogle Scholar
  49. 49.
    Yu MC, Yuan JM, Ross RK, Govindarajan S (1997) Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 25:226–228PubMedCrossRefGoogle Scholar
  50. 50.
    Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127(Suppl 1):S56–S61PubMedCrossRefGoogle Scholar
  51. 51.
    Pollicino T, Squadrito G, Cerenzia G et al (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:102–110PubMedCrossRefGoogle Scholar
  52. 52.
    Squadrito G, Pollicino T, Cacciola I et al (2006) Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 106:1326–1330PubMedCrossRefGoogle Scholar
  53. 53.
    Gocke DJ, Hsu K, Morgan C et al (1970) Association between polyarteritis and Australia antigen. Lancet 296:1149–1153CrossRefGoogle Scholar
  54. 54.
    Han SH (2004) Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 8:403–418PubMedCrossRefGoogle Scholar
  55. 55.
    Jori GP, Buonanno G (1972) Chronic hepatitis and cirrhosis of the liver in cryoglobulinemia. Gut 13:610–613PubMedCrossRefGoogle Scholar
  56. 56.
    Florin-Christensen A, Roux MEB, Arana RM (1974) Cryoglobulins in acute and chronic liver diseases. Clin Exp Immunol 16:599–605PubMedGoogle Scholar
  57. 57.
    Levo Y, Gorevic PD, Kassab HJ et al (1977) Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 296:1501–1504PubMedCrossRefGoogle Scholar
  58. 58.
    Dienstag JL, Wands JR, Isselbacher KJ (1977) Hepatitis B and essential mixed cryoglobulinemia. N Engl J Med 297:946–947PubMedGoogle Scholar
  59. 59.
    Popp JW Jr, Dienstag JL, Wands JR, Bloch KJ (1980) Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. Ann Intern Med 92:379–383PubMedCrossRefGoogle Scholar
  60. 60.
    Galli M (1991) Cryoglobulinaemia and serological markers of hepatitis viruses. Lancet 338:758–759PubMedCrossRefGoogle Scholar
  61. 61.
    Galli M, Monti G, Invernizzi F et al (1992) Hepatitis B virus-related markers in secondary and in essential mixed cryoglobulinemias: a multicenter study of 596 cases. The Italian group for the study of crioglobulinemias (GISC). Ann Ital Med Int 7:209–214PubMedGoogle Scholar
  62. 62.
    Galli M (1995) Viruses and cryoglobulinemia. Clin Exp Rheumatol 13(Suppl 13):S63–S70PubMedGoogle Scholar
  63. 63.
    Della Rossa A, Tavoni A, Lorefice P et al (2000) HBV and HCV infection, polyarteritis nodosa and mixed cryoglobulinemia: a case report. Clin Rheumatol 19:502–504PubMedCrossRefGoogle Scholar
  64. 64.
    Garcia de La Peña Lefebvre P, Mouthon L, Cohen P et al (2001) Polyarteritis nodosa and mixed cryoglobulinaemia related to hepatitis B and C virus coinfection. Ann Rheum Dis 60:1068–1069CrossRefGoogle Scholar
  65. 65.
    Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins. J Clin Pathol 55:4–13PubMedCrossRefGoogle Scholar
  66. 66.
    Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18:54–63PubMedGoogle Scholar
  67. 67.
    Coffin CS, Terrault NA (2009) Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect Ther 7:549–558PubMedCrossRefGoogle Scholar
  68. 68.
    Potthoff A, Wedemeyer H, Boecher WO et al (2008) The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 49:688–694PubMedCrossRefGoogle Scholar
  69. 69.
    Liu CJ, Chuang WL, Lee CM et al (2009) Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136:496–504PubMedCrossRefGoogle Scholar
  70. 70.
    Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539PubMedCrossRefGoogle Scholar
  71. 71.
    Carosi G, Rizzetto M (2008) Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 40:603–617PubMedCrossRefGoogle Scholar
  72. 72.
    European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242CrossRefGoogle Scholar
  73. 73.
    Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662PubMedCrossRefGoogle Scholar
  74. 74.
    Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335–1374PubMedCrossRefGoogle Scholar
  75. 75.
    Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases (2009) Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST expert opinion meeting. Dig Liver Dis 42:81–91Google Scholar
  76. 76.
    European Association for the Study of the Liver (2011) EASL clinical practice guidelines: management of hepatitis C infection. J Hepatol 55:245–64CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  1. 1.Department of Clinical Sciences “Luigi Sacco”, Section of Infectious and Tropical DiseasesUniversità di MilanoMilanItaly

Personalised recommendations